Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
about
Clinical applications of palifermin: amelioration of oral mucositis and other potential indicationsTLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?Fibroblast growth factors as tissue repair and regeneration therapeutics.CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantationPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation.Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation.New pharmacotherapy options for chemotherapy-induced alimentary mucositis.Improving engraftment and immune reconstitution in umbilical cord blood transplantation.Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.Efficacy of palifermin on oral mucositis and acute GVHD after hematopoietic stem cell transplantation (HSCT) in hematology malignancy patients: a meta-analysis of trials.FGF Family: From Drug Development to Clinical Application
P2860
Q26852139-76ECDCDE-A3DF-4F66-AE18-780B34F334EAQ27015742-C51F6571-9BD4-4D65-B8A6-EB3F5538D8C8Q28272364-D4A3EE69-5D8F-4B95-B468-47E6ED7C6714Q36403184-6FDE1FAB-64AB-49BF-A20C-52D35FB9BA3AQ37035815-B2454273-FC03-47E2-95ED-52F913DE19B9Q37616815-779F41A4-B2C2-4523-9610-702FCB5A1260Q38044278-A429B1A5-002A-4E96-BA46-0A4B9EE7866AQ38152186-9CCF2C9D-42A5-43D5-9374-62CD48A8B4C6Q38175515-1BCA704D-AAE7-4630-A108-51E1262128BDQ38194133-635B5A64-F2E7-427E-92A5-6189ECFA9F16Q38384344-EE322DC9-9216-4E36-9CE9-3A9E8E98D4C1Q38589005-59F53B6D-F2FF-4EC4-8B06-FAEEE4EC4412Q38640239-F0939ACF-CF0A-4D34-AE8E-5C39D2FAA9F8Q40264385-E9396C59-829D-401E-ABF7-86B356329D99Q45302802-976AA14D-8523-447C-B611-87E8DA8AAE98Q47753506-C82D8D0F-888B-4794-BE84-F079FD5FA3BCQ49332936-2376C6A2-6C95-41DF-9EF4-EE7554A6F658Q57116705-F2C57E0E-4E1B-4024-AE2D-6DC1B9E59AB0
P2860
Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Palifermin is efficacious in r ...... poietic stem cell transplants.
@ast
Palifermin is efficacious in r ...... poietic stem cell transplants.
@en
type
label
Palifermin is efficacious in r ...... poietic stem cell transplants.
@ast
Palifermin is efficacious in r ...... poietic stem cell transplants.
@en
prefLabel
Palifermin is efficacious in r ...... poietic stem cell transplants.
@ast
Palifermin is efficacious in r ...... poietic stem cell transplants.
@en
P2093
P2860
P356
P1476
Palifermin is efficacious in r ...... poietic stem cell transplants.
@en
P2093
A A Jakubowski
H Castro-Malaspina
J D Goldberg
M R M van den Brink
M-A Perales
P2860
P2888
P304
P356
10.1038/BMT.2012.115
P407
P577
2012-07-02T00:00:00Z
P5875
P6179
1016120746